It is made available under a CC-BY-NC-ND 4.0 International license .

1 Title:

- 2 Integration of rare large-effect expression variants improves polygenic risk prediction
- 3

4 Authors:

- Craig Smail^{1,2,*}, Nicole M. Ferraro¹, Matthew G. Durrant³, Abhiram S. Rao^{4,5}, Matthew Aguirre¹, 5
- Xin Li⁶, Michael J. Gloudemans¹, Themistocles L. Assimes^{7,8}, Charles Kooperberg⁹, Alexander 6
- P. Reiner¹⁰, Qin Hui^{11,12}, Jie Huang¹³, Christopher J. O'Donnell^{14,15,16}, Yan V. Sun^{11,12}, Million 7
- Veteran Program, Manuel A. Rivas¹, Stephen B. Montgomery^{3,4,*} 8
- 9

10 Affiliations:

- 11 Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA 1.
- 12 2. Genomic Medicine Center, Children's Mercy Research Institute and Children's Mercy Kansas City, Kansas City, 13 MO, USA
- 14 3. Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA
- 15 4. Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
- 16 5. Department of Bioengineering, Stanford University, Stanford, CA, USA
- 17 6. CAS Key Laboratory of Computational Biology, CAS-MPG Partner Institute for Computational Biology, Shanghai, 18 China
- 19 7. Palo Alto VA Health Care System, Palo Alto, CA, USA
- 20 8. Division of Cardiology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
- 21 Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA 9.
- 22 10. Department of Epidemiology, University of Washington, Seattle, WA, USA
- 23 11. Atlanta VA Health Care System, Decatur, GA, USA
- 24 12. Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, USA
- 25 13. Department of Global Health, Peking University School of Public Health, Beijing, China
- 26 14. Boston VA Health Care System, Boston, MA, USA
- 27 15. Division of Cardiology, Department of Medicine, Harvard Medical School, Boston, MA, USA
- 28 16. Division of Cardiology, Department of Medicine, Brigham Women's Hospital, Boston, MA, USA
- 29
- 30 * Corresponding authors: Craig Smail (csmail@cmh.edu)

31 Stephen Montgomery (smontgom@stanford.edu) (lead contact)

It is made available under a CC-BY-NC-ND 4.0 International license .

33 Summary

- 34 Polygenic risk scores (PRS) aim to quantify the contribution of multiple genetic loci to an
- 35 individual's likelihood of a complex trait or disease. However, existing PRS estimate genetic
- 36 liability using common genetic variants, excluding the impact of rare variants. We identified rare,
- 37 large-effect variants in individuals with outlier gene expression from the GTEx project and then
- 38 assessed their impact on PRS predictions in the UK Biobank (UKB). We observed large
- 39 deviations from the PRS-predicted phenotypes for carriers of multiple outlier rare variants; for
- 40 example, individuals classified as "low-risk" but in the top 1% of outlier rare variant burden had a
- 41 6-fold higher rate of severe obesity. We replicated these findings using data from the NHLBI
- 42 Trans-Omics for Precision Medicine (TOPMed) biobank and the Million Veteran Program, and
- 43 demonstrated that PRS across multiple traits will significantly benefit from the inclusion of rare
- 44 genetic variants.
- 45

46 Key words

47 Polygenic risk scores, rare variants, transcriptomics, complex disease, human genetics

It is made available under a CC-BY-NC-ND 4.0 International license .

48 Introduction

49

A major goal of complex disease genetics is predicting an individual's disease risk. Recent efforts have aimed at summarizing genome-wide risk for multiple traits and diseases using polygenic risk scores (PRS)^{1–6}, which are derived by summing genome-wide common genetic variants associated with a given phenotype. PRS have demonstrated stratification of genetic disease risk, but there remains substantial unexplained variability in these predictions. One potential explanation for this variability is the presence of rare variants with large phenotypic effects that are unaccounted for in PRS models².

57

However, despite known contributions of rare genetic variants to complex traits and diseases^{7,8}, rare variants are difficult to robustly characterize and integrate into PRS predictions due to their abundance in the genome, poor interpretability and sample size constraints. To in-part alleviate this challenge, it has previously been shown that individuals with outlier gene expression have an increased burden of rare variants proximal to the outlier gene^{9–12}, and that this subset of rare variants tend to have larger effects on traits and diseases^{13,14}.

64

65 Given the known large effects of rare variants linked to expression outliers - and that these 66 variants are not currently included in existing PRS - we sought to test whether this subset of 67 rare variants can aid in explaining instances where an individual's phenotype deviates from their 68 phenotype as predicted by their PRS. We present an approach that summarizes the phenotypic 69 effects in UKB¹⁵ of an increasing burden of rare variants associated with outlier gene expression 70 discovered in GTEx. We focus primarily on body mass index (BMI) and obesity given the growing public health emergency of severe obesity in the US and around the world¹⁶, the 71 72 availability of high-quality publicly-available PRS for BMI, known polygenicity, and sample size 73 considerations.

74

75 Results

76

77 Identification of rare, large-effect expression variants

78

79 To identify rare variants linked to gene expression outliers that could also be tested for their

- 80 effects on complex traits, we intersected the set of single nucleotide variants with gnomAD¹⁷
- 81 minor allele frequency (MAF) > 0 and < 1% identified in GTEx v7 with high-quality imputed

It is made available under a CC-BY-NC-ND 4.0 International license .

82 variants in the UKB (Fig. 1A). From a starting set of 6.134.805 unique rare variants, we 83 identified 1,307,023 (21.3%) variants also within the UKB (Fig. 1B). From this intersecting set, 84 we compared the set of variants found in GTEx outlier to non-outlier individuals to isolate the 85 subset of rare variants present in gene expression outlier individuals only. This process was 86 conducted in two ways; "top-outlier" where only rare variants from the most extreme outlier 87 individual(s) (maximum of two individuals per gene - most under-expressed and most overexpressed individuals, abs(Z)>2), and "all outliers" where all rare variants from individuals with 88 89 abs(Z)>2 were included (Methods; Sup. Table 1). Rare variants found in both outlier and non-90 outlier individuals were subsequently removed. Variants were then linked to a specific gene if they fell within the gene body or +/- 10 Kb (N genes: "top-outlier" = 3.732; "all-outliers" = 91 92 15,095). We consider the "top-outlier" as a high-confidence set, given that these variants are 93 found in the most extreme expression outliers. The "all-outlier" method allows us to expand the 94 range of variants, guided by the properties of the "top-outlier" variant set. We further defined a 95 corresponding set of non-outlier/control variants, matched on both the gnomAD MAF and CADD¹⁸ scores of outlier variants (**Methods**). 96

97

We observed that individuals were often carriers for multiple outlier rare variants. Considering a sample cohort of individuals from UKB (N = 120,944) (**Methods; Sup. Fig. 1**), each individual had an average of 23 ("top-outlier") and 304 ("all-outlier") outlier variants. To evaluate if these variants cumulatively were biased in effect direction (i.e. risk or protective) for a highly polygenic trait, we assessed UKB BMI GWAS effect directions and observed no significant differences. On average, individuals carried 11 potential protective rare variants and 12 potential risk variants using the "top-outlier" approach.

It is made available under a CC-BY-NC-ND 4.0 International license .



- 121
- 122

It is made available under a CC-BY-NC-ND 4.0 International license .

123 Large-effect, rare expression variants impact BMI and obesity in UK Biobank

124

To evaluate if rare expression outlier-associated variants had greater effect sizes than matched non-outlier variants (used as a control set), we focused on BMI and obesity GWAS from the UKB. We observed that a subset of outlier variants had relatively larger GWAS effects; for example, an outlier variant linked to the gene *FOXO3* has an effect size rank of 1/3059 in a 1 Mb locus (centered on the top genome-wide significant variant) (**Fig. 1C**), and among the top 0.07% of effect sizes overall, across all variants measured across the UKB for BMI.

132 To systematically assess whether these outlier variants had higher effect sizes than non-outlier 133 variants, we performed a permutation test (N permutations = 10,000) using outlier ("top-outlier"; 134 n variants = 8.272) and matched non-outlier variants (n variants = 29.659) that fall within 10kb of 135 any PRS variant to assess how often randomly-drawn outlier variants had larger effect sizes 136 than non-outlier variants. For BMI GWAS, we observed a mean odds ratio of 1.02 when 137 comparing outlier vs. non-outlier variants, and a mean odds ratio of 1 when comparing nonoutlier variants to themselves (Wilcoxon test, $P < 1 \times 10^{-16}$). For obesity GWAS (ICD-10 E66), we 138 139 observed an increased mean odds ratio of 1.1 (Wilcoxon test, $P < 1 \times 10^{-16}$) (Fig. 2A). When 140 increasing the outlier expression Z-score threshold, we observed progressively larger odds 141 ratios (mean odds ratio (BMI GWAS): abs(Z)>4 = 1.28; abs(Z)>6 = 1.58), but not when 142 comparing non-outlier variants only (mean odds ratio (BMI GWAS): abs(Z)>4 = 1; abs(Z)>6 = 1) (Wilcoxon test, $P < 1 \times 10^{-16}$ for both comparisons) (**Fig. 2B**). We replicated the permutation test 143 144 findings using a subset of the same rare variants that are also available in the Million Veteran 145 Program (MVP) BMI GWAS (N variants: outlier = 4,955; non-outlier = 18,145), and observed similar results (mean odds ratio: outlier vs. non-outlier = 1.05; non-outlier only = 1; $P < 1 \times 10^{-16}$) 146 147 (Fig. 2C). We further directly compared effect sizes between outlier and control variants and 148 observed significantly increased effect sizes for outlier variants that increased with outlier Z-149 score thresholds (**Fig. 2D**; Ansari test, $P < 1 \times 10^{-16}$ for all comparisons). 150

We next assessed whether outlier variant effects were concordant with predictions of effect direction from common variant associations. We compared GWAS effect direction between ciseQTLs and outlier variants for the same loci matched on slope (as an example, positive ciseQTL slope and over-expression outliers both leading to increased GWAS risk) (**Methods**). We stratified results by cis-eQTL variant GWAS p-value and outlier-associated variant Z-score, observing that variants identified in more-severe (by Z-score) expression outliers have overall

It is made available under a CC-BY-NC-ND 4.0 International license .

- 157 better concordance in GWAS effect direction with cis-eQTL variants, across genes. For
- 158 example, at a cis-eQTL variant GWAS P-value cutoff $\leq 1 \times 10^{-6}$, we observed 50, 96, and 100%
- 159 concordance for variants passing absolute Z-score thresholds of 2, 3, and 4, respectively (**Sup.**
- 160 **Fig. 2**).
- 161

162 Independent outlier gene count (IOGC) score stratifies BMI

163

164 To identify the impact of multiple outlier variants in an existing high-guality, publicly-available 165 BMI PRS, we used data from Khera et al. (2019)¹. We first obtained gnomAD AF for PRS 166 variants, and observed that these PRS alleles have a mean gnomAD AF = 0.49 (SD = 0.29) 167 (Fig. 2E). Plotting GWAS effect sizes by UKB allele count for an example locus (gene FOXO3) 168 further illustrates that PRS variants tend to be common variants with small effects (Fig. 2F). We 169 calculated PRS for each individual in our UKB validation cohort (N = 120,944) and observed the 170 expected gradients in mean BMI and weight increasing by PRS deciles (Sup. Fig. 3). We then 171 used a linear regression model to assess change in BMI given an individual's PRS, sex, age, 172 first ten components of genetic ancestry, genotyping array, and a score that quantifies the total 173 outlier-variant burden per individual, computed by subtracting total protective from total risk 174 outlier-variants collapsed to gene-level (Methods; Sup. Fig. 4). We refer to this score as the 175 independent outlier gene count (IOGC) score henceforth. We observed significant coefficient 176 estimates for 10/15 features in the model, including IOGC score (linear regression r = 0.015, P =177 7×10^{-7} (Sup. Fig. 5). We computed the rate of concordance in GWAS effect (i.e. risk/protective) 178 and outlier direction for outlier variants linked genes across UKB individuals, observing a rate of 179 concordance of 86.7% for individuals with >=2 outlier variants linked to each gene. This rate of 180 concordance is remarkably stable when increasing the outlier variant threshold per gene 181 (82.2%, 81.8%, 83.2%, for >= 3, 4, and 5 outlier variants, respectively).

182

183 We sought to clarify whether IOGC variants identified from outlier individuals in GTEx were 184 driving downstream effects on BMI in excess of what is observed by selecting random subsets 185 of non-outlier rare variants. We investigated this by first selecting random subsets of the 186 matched non-outlier variants (matching the number of outlier variants across permutations, N 187 variants = 8,272; N permutations = 10,000), observing that the IOGC beta estimate when using 188 outlier variants exceeds that which would be expected based on random subsets of non-outlier 189 variants (mean IOGC non-outlier = 0.0075; empirical P = 0.0012) (Sup. Fig. 6A), validating the 190 findings of the permutation test described in the previous section. Furthermore, when outliers

It is made available under a CC-BY-NC-ND 4.0 International license .

- where observed across more than one tissue, we observed a mean change in BMI of 0.015 kg/m² per unit change in IOGC score (linear regression, $P = 7 \times 10^{-7}$), whereas increasing this threshold to >= 10 tissues results in a greater than 5-fold increase in mean change in BMI to 0.08 kg/m² per unit change in IOGC score (linear regression, P = 0.04) (**Fig. 2G**). Using a permutation test of matched non-outlier variants (N permutations = 10,000), we again observed that outlier effects exceed that which would be expected using random subsets of rare variants
- 197 (Sup. Fig. 6B).
- 198
- 199 We further investigated whether the severity of outlier gene expression integrated into the IOGC
- 200 score affected change in BMI. We observed that at increasingly more-stringent Z-score
- 201 thresholds, mean change in BMI also increased (Fig. 2H) (abs(Z) 2-3, linear regression r =
- 202 0.008 ($P < 1 \times 10^{-6}$); abs(Z) 3-4, linear regression r = 0.009 ($P = 2 \times 10^{-6}$); abs(Z) 4-5, linear
- regression r = 0.014 ($P = 9 \times 10^{-4}$). Comparing variants identified in outlier genes with Z-score
- between abs(Z) 2-3 with abs(Z) 4-5, we observe a 75% increase in mean change in BMI per
- 205 unit change in IOGC score.
- 206
- 207

It is made available under a CC-BY-NC-ND 4.0 International license .



208

It is made available under a CC-BY-NC-ND 4.0 International license .

209 Figure 2. Characterizing outlier and non-outlier variants using large-scale GWAS. A. Distribution of 210 odds ratios from permutation testing (N permutations = 10,000) to assess relative effect size comparing 211 outlier- and non-outlier variants per gene in UKB GWAS for BMI (top) and obesity (bottom). Across each 212 permutation, the absolute effect size for a randomly-chosen outlier sample and matched non-outlier 213 sample was obtained for each gene and summed in a contingency matrix to quantify the number of genes 214 where the outlier variant had an absolute effect size greater than the non-outlier variant (blue shading). 215 This process was repeated for randomly selected non-outlier variants only (gray). P-values were obtained 216 using a Wilcoxon rank sum test. Subset to genes linked to PRS variants. B. Distribution of odds ratios 217 from permutation testing (N permutations = 10,000) (permutation testing method as detailed in (A.)). 218 across progressively more-stringent GTEx outlier Z-scores. Odds ratio increases as a function of outlier 219 Z-score. C. Distribution of odds ratios from permutation testing (N permutations = 10,000) (permutation 220 testing method as detailed in (A.)), using the Million Veteran Program (MVP) GWAS for BMI. D. 221 Dispersion of mean effect sizes per gene for outlier (blue) and non-outlier variants (gray) across genes 222 with variants overlapping a publicly-available PRS for BMI, stratified by GTEx outlier Z-score. P-values 223 were obtained using an Ansari Test. E. Distribution of gnomAD allele frequency for outlier-associated 224 (blue), and non-outlier (grey) variants, and variants included in a publicly-available PRS for body mass 225 index (red). Outlier- and non-outlier-associated variants are rarer than variants included in the PRS. F. 226 Example gene locus (FOXO3) containing a genome-wide significant hit in UKB BMI GWAS (GWAS ID 227 21001) (purple diamond). Effect sizes for each variant in locus are displayed on the y-axis and UKB allele 228 count for each variant is displayed on x-axis. Points are colored by LD (1000 Genomes phase 3, 229 European cohort). Outlier-associated variants are highlighted in blue, non-outlier-associated variants are 230 highlighted in gray, PRS variants are highlighted in red. Outlier-associated variants have largest effect 231 sizes in locus. PRS variants tend to be common with small effect size. G. Coefficient estimate for IOGC 232 score increases when subsetting to outlier-associated variants where variants are identified in outliers in 233 an increasing number of GTEx tissues. X-axis indicates tissue threshold (i.e. tissue count>=N). H. Mean 234 change in BMI per unit change in IOGC score at difference Z-score cutoffs. Variants identified in more-235 severe outliers (by abs(Z-score)) have larger effects on BMI.

236

Extreme IOGC scores lead to substantial deviation from PRS for BMI and obesity 238

From the analyses presented above, rare variants linked to outlier gene expression in GTEx had larger effects on BMI and rates of obesity, independent of PRS, and this effect is modulated by properties of outlier effects (i.e. multi-tissue outliers, outlier Z-score severity). We next sought to understand the magnitude of deviation from cohort-average BMI and obesity associated with outlier rare variant burden. For this analysis we used outlier-associated variants identified using

It is made available under a CC-BY-NC-ND 4.0 International license .

- the all-outlier method (Methods) this increases the range of IOGC scores we can interrogate
 (range: top-outlier = -19:20; all-outliers = -67:69).
- 246

We calculated the mean rate of change in BMI across different percentiles of IOGC score using a linear regression model, adjusting for PRS, age, sex, first ten principal components of ancestry, and genotyping array. Each increment in IOGC score percentile bin is associated with a mean rate of change in BMI of 0.05 kg/m² (linear regression, $P < 1 \times 10^{-16}$); comparing bottom and top 0.05% percentiles, this results in a difference in mean BMI of 0.74 kg/m² (**Fig. 3A**). In the regression model, we tested for an interaction between PRS and IOGC score and observed no significant effect.

254

Rates of obesity (BMI >= 30 kg/m²) and severe obesity (BMI >= 40 kg/m²) for individuals in the extreme 0.5% IOGC score percentiles deviate from the average rates of the full cohort overall: obesity: 0.5 percentile = 20.8%; 99.5 percentile = 26.6%; average overall: 24.5% (logistic regression, $P = 5.3 \times 10^{-14}$); severe obesity: 0.5 percentile = 1%; 99.5 percentile = 3.5%; average overall: 1.9% (logistic regression, P = 0.001) (**Fig. 3B**). We also tested for risk of being underweight (BMI<18.5 kg/m²) and found an inverse relationship (i.e. lower IOGC score percentile increases risk of being underweight) (logistic regression, P = 0.003).

263 Individuals in extreme IOGC score percentiles further differed in their age of onset of obesity 264 and high blood pressure diagnosis (where high blood pressure is used as a proxy for 265 hypertension). For diagnosis of obesity, individuals in IOGC score percentile <=1%, mean age 266 of onset obesity = 59.41, whereas individuals in IOGC score percentile >=99%, mean age of 267 onset = 56.95, a difference of in age of onset of 2.46 years (Wilcoxon test, P = 0.03). For high 268 blood pressure diagnosis, individuals in IOGC score percentile <=1%, mean age of onset = 269 53.04, whereas individuals in IOGC score percentile >=99%, mean age of onset = 50.44, a 270 difference of 2.6 years (Wilcoxon test, P = 0.004) (Fig. 3C).

271

We also observed that effects of outlier rare variants can manifest from childhood. We identified a subset of individuals in the UKB validation cohort (N=55,126) who provided self-reported information on being "plumper" or "thinner" than average at age 10 (UKB data field #1687). We tested the association of IOGC score with childhood body size using a logistic regression model (where the response was coded as 0="thinner", 1="plumper"). The model was adjusted for PRS, age, sex, and first ten principal components of ancestry. For each unit change in IOGC score,

It is made available under a CC-BY-NC-ND 4.0 International license .

we observed an increase in the odds of having a "plumper" comparative body size at 10 of 1.001 (logistic regression, $P = 3 \times 10^{-09}$).

280

281 We next sought to understand the potential magnitude of deviation in PRS-predicted rate of 282 severe obesity (BMI >= 40 kg/m²) associated with extreme IOGC score. We first stratified 283 individuals by PRS: "low-risk" (PRS decile 1); "high-risk" (PRS decile 10), and further subset by 284 increasingly stringent percentiles of IOGC score (Table 1). We computed empirical P-values 285 using a permutation test (N permutations = 10,000) to understand how likely the rates of severe 286 obesity are observed across random subsets of individuals from within the same PRS groups. 287 From this analysis we observed, for example, that "low-risk" individuals (PRS decile 1) in the 288 99th percentile of IOGC score have a rate of severe obesity approaching the average rate for 289 PRS decile 10 (4.55%, P = 0.0009), a greater than 6-fold increase in the PRS-predicted rate of

- 290 severe obesity.
- 291

292 Table 1. Rates of severe obesity as a function of PRS and IOGC

| IOGC percentile | <=0.25% | <=0.5% | <=1% | <=10% | PRS only | >=90% | >=99% | >=99.5% | >=99.75% |
|---------------------------|----------------------------|----------------------------|-----------------------------|----------------------------------|----------------------|--------------------------|---------------------------------------|--------------------------------------|-------------------------------------|
| PRS bin 1 "low-risk" | 0% (n: 45) <i>NS</i> | 0% (n: 84) <i>NS</i> | 0% (n: 171) <i>NS</i> | 0.66% (n: 1,351) <i>NS</i> | 0.67% (n: 12,094) | 1.01% (n: 992) NS | 4.55% (n: 110) <i>P</i> =0.0009 | 6.35% (n: 63) <i>P</i> =0.0006 | 6.06% (n: 33) <i>P</i> =0.02 |
| PRS bin 10 "high-risk" | 0% (n: 27) NS | 1.72% (n: 58) NS | 2.65% (n: 113) NS | 4.08% (n: 1152) NS | 4.99% (n: 12,043) | 5.28% (n: 1137) NS | 7.63% (n: 118) NS | 10.35% (n: 58) NS | 16.67% (n: 30) <i>P</i> =0.02 |

²⁹³

* P-values are calculated empirically across 10,000 permutations

294

295 We performed regression modelling within the "low-risk" and "high-risk" PRS groups described

above, and observed similar linear regression coefficients per change in IOGC score percentile

bin (linear regression; PRS bin 1: r = 0.06 ($P = 3 \times 10^{-5}$); PRS bin 10: r = 0.11 ($P = 7 \times 10^{-7}$) (**Fig.**

3D). We next investigated the composition of outlier variants among individuals with outlier

299 IOGC scores (specifically, bottom and top 10% of IOGC score distribution). For each individual

300 in this set, we calculated the IOGC-aware deviation (i.e. below mean for low IOGC individuals,

- and above mean for high IOGC individuals) from within-group PRS mean BMI (as Z-score) and
- 302 looked for differences in the relative composition of outlier variants in individuals near the mean
- 303 (abs(Z-score)>0 and <0.5) and far from mean (abs(Z-score)>=3). We observed that individuals

304 far from their predicted PRS mean were enriched for missense and splicing outlier variants

305 (Fisher's Exact Test; missense: odds ratio = 1.27 (Cl 1.14 - 1.40), $P = 8 \times 10^{-6}$; splicing: odds

It is made available under a CC-BY-NC-ND 4.0 International license .

ratio = 1.25 (Cl 0.98 – 1.58), P = 0.05) (Sup. Fig. 7). This finding suggests that variant
annotations could be integrated in to future iterations of IOGC to further increase the predictive
power of the score. Furthermore, we computed IOGC scores across genes summarized by their
effect in the PRS (using the maximum effect weight per PRS variant mapped to within each
gene), observing that IOGC score increases as a function of gene PRS effect size (Sup. Fig. 8).
This results demonstrates that IOGC score is increased in genes with known larger effects on
BMI.

313

314 Replication in TOPMed WHI

315

316 We replicated our findings using TOPMed WHI data, subset to individuals with European 317 ancestry and with genetic and phenotypic data available (N = 6.501). We constructed a linear 318 regression model including PRS, first ten principal components of ancestry, age, and IOGC 319 score (sex is not included since TOPMed WHI is an all-female cohort). Variant effect directions 320 were obtained from UKB GWAS, as above. IOGC score is again a significant predictor of BMI (mean change in BMI per quantile of IOGC score: linear regression r = 0.13 kg/m², P = 0.03) 321 322 (Fig. 3E). Although explicitly tested in the regression model, we visually compared the PRS of 323 individuals in the 10th and 90th percentile of IOGC score and observed no significant 324 differences in PRS for these two groups (**Sup. Fig. 9**). In the regression model, we again tested 325 for an interaction between PRS and IOGC score and observed no significant effect. 326 327 Similar to observations in UKB, rates of obesity (BMI >= 30 kg/m^2) and severe obesity (BMI >= 40 kg/m²) for individuals in the 10th and 90th percentiles for IOGC score deviated from the 328 329 average rates of the full cohort overall: obesity: 10^{th} percentile = 31.03%; 90^{th} percentile = 330 35.30%; average overall: 33.49% (**Sup. Fig. 10**); severe obesity: 10^{th} percentile = 3.67%; 90^{th} 331 percentile = 5.43%; average overall: 4.59% (Fig. 3E). 332 333 Subsetting by multi-tissue outlier-associated variants (N tissues ≥ 10), we again observed a 334 significant effect of IOGC score independent from PRS, age and genetic ancestry (mean

- change in BMI per quantile of IOGC score: linear regression $r = 0.20 \text{ kg/m}^2$, P = 0.01). Further
- highlighting the independence of IOGC score from PRS, risk of obesity and severe obesity
- among individuals within PRS decile 10 ("high-risk") can vary substantially from average for
- individuals in the 10th and 90th percentile of IOGC score (**Fig. 3F**).

It is made available under a CC-BY-NC-ND 4.0 International license .



339

340 Figure 3. Increasing burden of outlier variants is associated with significant deviation in PRS-341 predicted body mass index and obesity. A. Mean BMI at different percentiles of IOGC score and linear 342 regression fit. Dashed line indicates overall cohort mean. B. Rate of obesity and severe obesity for 343 individuals with extreme IOGC scores (0.5% and 99.5% percentiles). Logistic regression results: obesity: 344 1.003 ($P = 1.20 \times 10^{-14}$); severe obesity: 1.004 (P = 0.0009). Dashed line indicates overall cohort mean. **C**. 345 Age of onset of obesity and high blood pressure diagnosis for individuals with extreme IOGC scores. 346 Obesity diagnosis: percentile <=1%: mean age of onset obesity = 59.41; percentile >=99%: mean age of 347 onset 56.95 (P = 0.03), mean difference of 2.46 years; high blood pressure diagnosis: percentile <=1%: 348 mean age of onset high blood pressure = 53.04; percentile >=99%: 50.44 (P = 0.004), mean difference of 349 2.6 years. D. Mean BMI at different percentiles of IOGC score, computed separately in PRS bins 1 and 350 10. Dashed line indicates the mean rate within each PRS group. E. Mean BMI (left) and incidence of 351 severe obesity (right) at different percentiles of IOGC score, including linear regression fit, in TOPMed 352 WHI. Dashed line indicates overall cohort mean. F. Mean incidence of obesity (top) and severe obesity 353 (bottom) for TOPMed WHI PRS decile 10 cohort, using outlier variants with multi-tissue outlier count 354 >=10. Dashed line indicates overall cohort mean for PRS decile. 355 356 357

It is made available under a CC-BY-NC-ND 4.0 International license .

| 359 | Rare variants impact PRS prediction across multiple traits and diseases |
|-----|---|
| 360 | |
| 361 | The main focus of our study was on BMI and associated rates of obesity, but the same |
| 362 | approach can be applied to many other traits and diseases. For example, using a publicly- |
| 363 | available PRS for type-2 diabetes (T2D, Methods), we observed a deviation from PRS- |
| 364 | predicted mean incidence of diabetes associated with an increasing burden of outlier variants |
| 365 | (IOGC <i>r</i> = 1.01, <i>P</i> = 0.03, logistic regression) (Fig. 4A). Looking at age of T2D onset in a cohort |
| 366 | defined as "high-risk" by PRS (PRS Z-score > 1), we observe a difference in mean age of onset |
| 367 | of 4.04 years (Wilcoxon test, $P = 0.02$), comparing individuals in the 10 th and 90 th percentiles of |
| 368 | IOGC score among this PRS high-risk group (Fig. 4B). |
| 369 | |
| 370 | To quantify differences in effect sizes of outlier-associated variants across diverse traits and |
| 371 | disease, we repeated the same permutation test described earlier (Methods), utilizing all |
| 372 | outlier- and non-outlier variants identified using the "top-outlier" method across 2,419 traits and |
| 373 | diseases released in UKB Phase 1 GWAS (N permutations = 1,000). We observed a mean |
| 374 | odds ratio of 1.05 (SD = 0.06) across all disease and traits when comparing outlier vs. non- |
| 375 | outlier variants, and a mean odds ratio of 1 (SD = 0.002) for non-outlier variants only (Wilcoxon |
| 376 | test, $P < 2 \times 10^{-16}$) (Fig. 4C). Increasing the outlier Z-score threshold, we observed an increasing |
| 377 | trend for observing outlier variants with top effect sizes (mean odds (SD): abs(Z-score)>4 = 1.10 |
| 378 | (0.14); abs(Z-score)>6 = 1.17 (0.25) (Wilcoxon test, $P < 1 \times 10^{-16}$ both comparisons). No |
| 379 | difference was observed in odds ratios when comparing non-outlier variants only. |
| 380 | |
| 381 | Across different GWAS meta-categories (cancer, illnesses, physical traits, cause of death), we |
| 382 | observed the same overall trend for observing outlier variants with top GWAS effect sizes, |
| 383 | increasing with Z-score threshold ($P < 2 \times 10^{-16}$ for all outlier vs. non-outlier comparisons) (Fig. |
| 384 | 4D). For example, for breast cancer (ICD-10: C50, Malignant neoplasms of breast), we |
| 385 | observed odds ratios 1.02, 1.11, 1.25 for abs(Z-score)>2, 4 and 6, respectively. We also |
| 386 | expected some GWAS traits to not be sensitive to SNPs linked to gene outlier effects. We |
| 387 | explored this hypothesis by manually selecting several traits where genetic relationships are |
| 388 | more speculative (i.e. loud music exposure, transport for commuting to job) and observed no |
| 389 | difference in the distribution of odds ratios comparing outlier vs. non-outlier variants and non- |
| 390 | outlier variants only (Sup. Fig. 11). |

It is made available under a CC-BY-NC-ND 4.0 International license .



391

392 Figure 4. Extending the method to diverse traits and diseases. A. Deviation from PRS-predicted 393 mean incidence of diabetes (%) amongst individuals with extreme IOGC scores, and average score. 394 Logistic regression: beta = 1.01 (P = 0.03). Dashed line shows the average incidence of diabetes for each 395 PRS bin. Low-risk = PRS bin 1 of 5 (PRS Z-score < -0.84); High-risk = PRS bin 5 of 5 (PRS Z-score > 396 0.84). B. Age on onset of diabetes in PRS z-score > 1 cohort: difference in mean age of onset = 4.04 397 years (Wilcoxon test, P = 0.02). C. Distribution of mean odds ratio per UKB GWAS phenotype across 398 1,000 permutations for outlier-vs. non-outlier associated variants (blue) and non-outlier vs. non-outlier 399 variants (gray) (Wilcoxon test, P<2×10⁻¹⁶). **D.** Distribution of mean odds ratio per UKB GWAS phenotype 400 (meta-groups: cancer; illnesses; physical; primary cause of death) across 1,000 permutations for outlier-401 vs. non-outlier associated variants (blue) and non-outlier vs. non-outlier associated variants. Analysis was 402 repeated at increasing thresholds of outlier gene expression absolute Z-score (from abs(Z-score)>=2 to 403 abs(Z-score) >= 6).

404

405 Discussion

406

407 Integration of rare variants within polygenic risk predictions is a major challenge. We have

408 demonstrated that a high burden of rare variants can lead to substantial deviations in PRS-

409 predicted phenotype. Furthermore, by integrating rare variants into genetic risk prediction using

410 the IOGC score, we demonstrate improvements in predicting risk for multiple traits and

It is made available under a CC-BY-NC-ND 4.0 International license .

- diseases. Specifically, for BMI we demonstrate that PRS "low-risk" individuals who are in the top
- 412 1% of IOGC have a rate of severe obesity (BMI>=40 kg/m²) approaching the average rate for
- 413 PRS "high-risk" individuals. By leveraging diverse traits and diseases recorded in the UKB we
- 414 further demonstrate applications for diverse polygenic phenotypes.
- 415
- 416 Notably, the power of this approach is enabled by first isolating rare, expression outlier-linked 417 variants in GTEx. Given that this cohort is limited to 546 individuals, it is certain that many large-418 effect variants impacting expression remain to be identified. Future large-scale RNA-sequencing 419 studies and catalogues of outlier-associated rare variants will only increase the efficacy of this 420 approach. Furthermore, we could recover only a subset of outlier-associated rare variants in 421 UKB, due to limitations in imputation; future WGS in population biobanks will recover more rare, 422 outlier-associated variants. Future WGS will also expand the frequency spectra that can be 423 interrogated - carriers of ultra-rare, outlier variants are likely to have even larger effects and impacts on the IOGC score^{19–21}. Additionally, future work could integrate other data modalities 424 425 (e.g. single cell, proteomics outliers).
- 426

427 Our study offers a baseline of phenotypic effects of rare, large-effect variants and shows

428 considerable impact in aiding the prediction of individual phenotypes. As with current genetic

- risk prediction, we expect that the IOGC score can immediately help to better identify and
- 430 stratify high-risk individuals into specific early treatments. Overall, this work has important

431 immediate implications for the implementation of genetic risk prediction in standard clinical care.

432

It is made available under a CC-BY-NC-ND 4.0 International license .

434 Methods

435

436 GTEx v7 data

437 Processed WGS variant data was obtained from GTEx v7 (see Resource Availability). Using 438 the software bedtools²² (--window flag), variants were linked to genes if falling within the gene 439 body, 10 Kb upstream of transcription start start, or 10 Kb downstream of the transcription end 440 site. Using the software Vcfanno²³, SNP variants were intersected with gnomAD (version 441 r2.0.2)¹⁷ and CADD¹⁸ databases to obtain the minor allele frequency and CADD score, 442 respectively, for each variant. Variant annotations were obtained using Variant Effect Predictor 443 (VEP) (version 88)²⁴. Minor allele frequencies were calculated across all individuals in gnomAD. 444 Non-SNP (i.e. indel, SNV) variants were discarded. SNPs were retained if the gnomAD MAF fell 445 in the range 0<MAF<1%. Multi-allelic SNPs were removed (multi-allelic in gnomAD). Finally. 446 SNPs were required to have been directly measured or imputed in UKB Phase 1 GWAS (imputation quality as described in $[^{25}]$, namely: UKB MAF > 0.1%; Hardy-Weinberg Equilibrium 447

448 P > 1×10^{-10} ; INFO score > 0.8).

449

450 Processed RNA-sequencing data was obtained from GTEx v7 (see **Resource Availability**). To 451 identify GTEx outlier gene expression samples, normalized gene expression values (FPKM) 452 were processed across all GTEx v7 tissues. limited to autosomal genes annotated as protein 453 coding or long non-coding RNA genes in GENCODE v19. A minimum expression filter was 454 applied per gene (>=10 individuals with FPKM > 0.1 and read count > 6); genes not passing this filter were removed. Expression values were PEER²⁶ factor corrected (using 15 factors for 455 456 tissues with ≤ 150 samples, 30 for tissues with ≤ 250 samples, and 35 for tissues with > 250457 samples), then scaled and centered to generate expression Z-scores. Individuals exhibiting 458 global patterns of outlier gene expression for a given tissue were removed from the final 459 corrected expression matrix for that tissue. Global outlier is defined as any individual who has 460 the most-extreme absolute Z-score of corrected gene expression in 100 or more genes in a 461 given tissue at an outlier cutoff of abs(Z-score)>2.

462

463 UK Biobank data

UKB Phase 1 GWAS summary statistics were downloaded from the Neale Lab server (available
at http://www.nealelab.is/uk-biobank). Summary statistics for each GTEx outlier and non-outlier
variant were joined on chromosome, position, ref, and alt columns, using hg19 coordinates. All
other phenotypic and genotypic data were sourced from the data instance approved under UKB

It is made available under a CC-BY-NC-ND 4.0 International license .

468 application #24983 (see **Resource Availability**). Individual-level phenotypes for weight (UKB 469 data field #21002), body mass index (UKB data field #21001) and diabetes (UKB data field 470 #2443) were downloaded from the relevant phenotype file. For weight and BMI, we averaged 471 (using the median) over all observations per-individual for those individuals with multiple 472 observations for the same phenotype. Imputed and directly measured genotypes for all variants 473 used in this study were extracted from the genotyping callset (version 3). Additional phenotypic 474 and demographic data used included: age, sex, principal components, genotyping array (all 475 included in the UKB sample QC file); age of onset of diagnosis (obesity (UKB data field 476 #130792), high blood pressure (UKB data field #2966), diabetes (UKB data field #2976)); and 477 comparative body size at age 10 (UKB data field #1687).

478

479 TOPMed Women's Health Initiative (WHI) data

480 The full TOPMed WHI cohort was first subset to self-reported European ancestry only (race 481 code '5' in file WHI.phv00078450.v6.p3.c1.txt). Individual-level weight and BMI measurements 482 were obtained from the file phs000200.v11.pht001019.v6.p3.c1.f80 rel1.HMB-IRB.txt.gz. The 483 average (median) was found for individuals with multiple observations of the same phenotype. 484 Genotypes were obtained from whole genome sequencing data available in the archive 485 phg001146.v1.TOPMed WGS WHI.genotype-calls-vcf.c1.HMB-IRB.tar. BED files were created using the software plink (version 2.0)²⁷. TOPMed WHI bed files are in hg38 assembly: we used 486 487 the software CrossMap²⁸ to convert genome coordinates from hg19 to hg38 assemblies for the 488 purposes of measuring GTEx outlier and non-outlier variants among TOPMed WHI individuals 489 and computing polygenic risk scores.

490

491 Genotype principal components we computed using a random selection of common variants 492 (N=50,000) available in UKB; we chose to leverage UK Biobank allele count information to 493 define a set of high-confidence common variants (UKB minor allele count > 50,000), given the 494 increased sample size of UKB compared with TOPMed WHI. Genotypes were extracted using 495 plink (version 2.0). To create the input matrix for computed principal components, the genotypes 496 of each extracted variant was imported and checked for minor allele variants and the 497 percentage of missing genotypes; alles with zero minor allele variants and/or >1% missingness 498 were removed. For variants with >0 and <=1% genotype missingness, missing genotypes were 499 replaced by the mode for that particular variant. Principal components were computed using the 500 software flashpca²⁹.

It is made available under a CC-BY-NC-ND 4.0 International license .

502 Million Veteran Program (MVP) GWAS for body mass index

- 503 DNA extracted from participants' blood was genotyped using a customized Affymetrix Axiom®
- 504 biobank array, the MVP 1.0 Genotyping Array. The array was enriched for both common and
- 505 rare genetic variants of clinical significance in different ethnic backgrounds. Quality-control
- 506 procedures used to assign ancestry, remove low-quality samples and variants, and perform
- 507 genotype imputation to the 1000 Genomes reference panel were previously described³⁰.
- 508 Individuals related more than second degree cousins were excluded.
- 509
- 510 We recently conducted HARE (Harmonized ancestry and Race/Ethnicity) analysis using
- 511 race/ethnicity information from MVP participants³¹. Genotyped MVP participants are assigned
- 512 into one of the four HARE groups (Hispanics, non-Hispanics White, non-Hispanics Black, and
- 513 non-Hispanics Asian) and "Other". The analysis is based on a machine learning algorithm,
- 514 which integrates race/ethnicity information from MVP baseline survey and high-density genetic
- 515 variation data. Trans-ethnic, and ethnicity-specific principal component analyses were
- 516 performed using flashPCA²⁹. BMI was calculated as average BMI using all measurements within
- 517 a three-year window around the date of MVP enrollment (i.e., 1.5 years before/after the date of
- enrollment), excluding height measurements that were >3 inches or weight measurements >60
- 519 pounds from the average of each participant.
- 520

521 Genetic association with BMI in the MVP cohort was examined among 217,980 non-Hispanic 522 White participants. BMI was stratified by sex and adjusted for age, age-squared, and the top ten 523 genotype-derived principal components in a linear regression model. The resulting residuals 524 were transformed to approximate normality using inverse normal scores. Imputed and directly 525 measured genetic variants were tested for association with the inverse normal transformed 526 residuals of BMI through linear regression assuming an additive genetic model.

527

528 Isolating rare variants observed in GTEx gene expression outliers and non-outliers

529 Rare variants occurring in gene expression outlier individuals are identified using two methods;

- 530 namely, top-outlier and all-outliers. Both approaches start with genetic and transcriptomic data
- 531 processed as detailed above ("GTEx v7 genetic and transcriptomic data"). Using the top-outlier
- 532 approach, variants were aggregated across all individuals and subset to gnomAD MAF > 0 and
- 533 < 1%. This list was then tabulated to obtain a count of unique individuals with each variant; any
- variant observed in > 1 individual was removed. As a further filtering step, variants were
- retained only if they were included in UKB Phase 1 GWAS. To link variants to expression

It is made available under a CC-BY-NC-ND 4.0 International license .

536 outliers, we identified for each tissue the individuals with the least or most expression per gene 537 (i.e. under-expression outlier and over-expression outlier), removing any results falling below a 538 predefined Z-score threshold of abs(Z-score) < 2. We also defined, for each tissue and gene, a 539 set of individuals with non-outlier gene expression (defined as abs(Z-score)<1). Non-outlier 540 variants were filtered to match the CADD score (within a window +/- 5) of any outlier variants for 541 each tissue/gene/outlier direction triple; this is important for genes with both an under-542 expression and over-expression outlier, as subsequent permutation testing uses outlier and 543 non-outlier variants matched on a CADD score window. Variants identified in outliers in >=1 544 tissue were ignored when identifying matching non-outlier variants; in this way, a putatively 545 causal large-effect expression variant (in any number of tissues) would not be counted in both 546 outlier and non-outlier variant sets. For the all-outliers method, we removed any outlier variant 547 also identified in ≥ 1 non-outlier individual: this differs from the top-outlier method, in which 548 outlier variants identified in any other individual (regardless of outlier status) are removed. We 549 did not define a matching set of non-outlier variants in the all-outliers method, due to run-time 550 constraints on the computational pipeline developed for this study. For both methods, we 551 recorded the number of tissues in which each outlier variant was identified (for variants 552 identified in >1 tissue, we refer to these as multi-tissue outlier variants).

553

554 <u>GWAS effect size permutation test</u>

555 We performed a permutation test to study differences in GWAS effect sizes for GTEx outlier and 556 non-outlier variants. This test was repeated for two independent GWAS cohorts: UK Biobank 557 and Million Veteran Program. For each GWAS, the input data is a file containing outlier and 558 non-outlier variants with associated GWAS effect size (i.e. beta estimate), linked outlier gene, 559 GTEx sample ID, outlier direction (under-expression/over-expression), and outlier tissue. 560 Additionally, for GWAS of traits and disease where we also run a separate test after integrating 561 PRS information, subsetting genes to those linked to any outlier variant falling within 10 Kb of a 562 PRS variant. To define a set of outlier and non-outlier variants, we first subset outlier variants 563 using a defined absolute Z-score of outlier gene expression, then find the intersection (using 564 tissue, gene, and outlier direction) between the outlier variants that pass the Z-score thresholds 565 and the matched non-outlier controls. This step ensures we have sufficient data to randomly 566 select exactly one outlier and non-outlier variant per tissue/gene/outlier direction triple (we refer 567 to this as an outlier triple), per permutation. The permutation test is based on the results of the 568 top-outlier methods (see previous section); therefore, there is exactly one outlier individual per 569 outlier triple. However, for non-outlier variants, there can be matched variants identified in > 1

It is made available under a CC-BY-NC-ND 4.0 International license .

570 unique individual. We subset randomly to one non-outlier individual per outlier triple, then 571 randomly select exactly one outlier and non-outlier variant per outlier triple. For each outlier 572 triple, we then count which variant is associated with the greater GWAS absolute effect size 573 (outlier/non-outlier); this information can then be summarized in a contingency table, which is 574 then used as the input to compute an odds ratio. We repeated this analysis for a file containing 575 non-outlier variants only, which follows the same method described above, comparing two 576 randomly chosen non-outlier variants per outlier triple, for outlier triples with non-outlier variants 577 from >= 2 unique non-outlier individuals.

578

579 <u>Calculating polygenic risk scores</u>

580 We computed polygenic risk scores (PRS) for the UKB and TOPMed WHI cohorts in this study.

581 Two high-quality, publicly-available PRS were used (see **Resource Availability**): body mass

582 index (Khera.et.al_GPS_BMI_Cell_2019.txt.zip); and type-2 diabetes

583 (Type2Diabetes_PRS_LDpred_rho0.01_v3.txt). Scores were calculated using the software plink

584 (version 2.0) (--score flag). PRS variant coordinates were first converted to hg38 assembly

585 using CrossMap²⁸ for calculating PRS scores in the TOPMed WHI cohort. Scores were

586 calculated separately for each chromosome, then summed per individual and scaled to

587 generate Z-scores.

588

589 <u>GTEx eQTL to assess concordance in GWAS effect direction between eQTL and outlier</u>

590 variants

591 GTEx eQTL summary statistics were downloaded and filtered on P-value (using column

592 "pval_nominal") with threshold $P<1\times10^{-18}$. Remaining variants were linked to their GWAS effect

size (i.e. protective or risk). For genes with >1 eQTL passing the P-value threshold, the variant

594 with the smallest UKB GWAS P-value was retained. This step was computed separately for

each GTEx tissue. We used a majority-rule approach to assign a single, high-quality consensus

596 GWAS effect direction per gene, based on the median slope estimate and GWAS effect

597 direction across all top eQTL variants per tissue that passed the two P-value filtering steps. For

598 example, if a given gene consisted of 10 eQTL risk variants and 5 protective risk variants, the

- 599 gene would be assigned a "risk" label. We removed any genes where a majority GWAS effect
- 600 direction could not be computed (i.e. an equal number of protective and risk effects), genes
- 601 where eQTL risk variants shared a median slope that matched the median slope of eQTL
- protective variants (e.g. positive slope in both cases), and genes where the slope of any eQTL
- risk variant matches the slope of any eQTL protective variant. Outlier variants are then

It is made available under a CC-BY-NC-ND 4.0 International license .

- 604 compared on the slope and GWAS effect direction of the consensus eQTL results (e.g. for a
- 605 given gene with positive median slope and GWAS risk effect, we assessed if the outlier variant
- 606 was an over-expression outlier variant and its comparable relationship to GWAS risk).
- 607

608 Inferring UKB non-British white validation cohort

Using the self-identified non-British white labels that were reported in the UKB metadata, a

- 610 larger cohort of predicted non-British white individuals was inferred. For all self-reported non-
- British white individuals, the mean and standard deviation of the first and second genotypic
- 612 principal components were calculated. All individuals without a self-reported ethnic identity that
- 613 were within +/- 3 SD of the calculated mean PC1 and PC2 values were inferred to be non-
- British white. All self-reported non-British white individuals that fell out of this range were also
- 615 excluded. This final cohort consisted of 23,790 self-reported non-British individuals, and 97,154
- 616 inferred non-British white individuals. We found that the PRS distribution of this non-British white
- 617 cohort did not differ significantly from a normal distribution (Shapiro-Wilk normality test; *P* =
- 618 0.2774), suggesting that the PRS as calculated on the British white cohort generalizes well to619 this cohort.
- 620

621 Quantifying effect on phenotypes associated with IOGC score

622 Using the list of GTEx outlier variants linked to genes, we retained the genes in which ≥ 1 623 outlier variant overlapped any PRS variants (within a +/- 10 Kb window). In this way, we focus 624 only on genes previously linked to the phenotype (and therefore included in the PRS). The 625 resulting set of outlier- and non-outlier variants in retained genes were written to a lookup file 626 which was then input to the software plink²⁷ (--extract flag) to identify UKB individuals in the 627 validation cohort who are heterozygous or homozygous for each variant (i.e. alternate allele 628 genotype 1 and 2, respectively). We then used previously-released UKB GWAS effect estimates 629 to assign effect directions to each outlier variant (i.e. risk/protective). Given that the previously-630 released GWAS were calculated on UKB individuals with white British genetic ancestry (see²⁵), 631 the non-British white cohort validation cohort we constructed for this study, as well as the 632 TOPMed WHI cohort, was non-overlapping.

633

We quantified the effect of outlier variant burden on phenotype by computing a score that summarizes, per individual, putative outlier gene burden. We refer to this quantity as the independent outlier gene count (IOGC). To compute this score, for each individual we link

It is made available under a CC-BY-NC-ND 4.0 International license .

variants to effect size direction in UKB, then collapse to gene-level to prevent double-counting.
Per individual, we convert the beta effect estimate per variant to integers using a sign function:

640
$$sgn(\beta_k) \coloneqq \begin{cases} -1 & if \ \beta_k < 0, \\ 0 & if \ \beta_k = 0, \\ 1 & if \ \beta_k > 0. \end{cases}$$

641

642 , where β is the UKB GWAS beta coefficient for variant *k*. In practice, effect sizes of zero are 643 not generally observed, so we expect to see only values of -1 or 1. Following this step, we take 644 the distinct values per gene (i.e. remove duplicates); since our goal is to use outlier variants to 645 tag outlier/dysregulated gene expression, this step prevents counting of putative outlier gene 646 expression more than once. Therefore, if we denote the vector of $sgn(\beta_k)$ for variants linked to 647 a given gene as *s*, then:

648

649
$$\theta(s) = \{s_i\}_{i \in \{1,...,n\}}$$
, where $s = [s_i, ..., s_n]$

650

This is repeated across all genes g linked to >=1 outlier variant, and summed to yield the IOGC score for each individual j:

$$IOGC_j = \sum_{i=1}^g \theta(s)_i$$

654

Linear regression was used for quantitative phenotypes, and logistic regression for binary
phenotypes. In the regression models, we adjusted for PRS, age, sex (UKB only since TOPMed
WHI is a female-only cohort), first ten principal components of genetic ancestry, and genotyping
array (UKB only).

659

All statistical analyses were performed using R (version 3.6.0). Plots were generated using
 ggplot2 (version 3.3.0)³².

It is made available under a CC-BY-NC-ND 4.0 International license .

664 **Resource availability**

- 665 GTEx (v7) RNA-seq and WGS data is available from dbGaP (dbGaP Accession phs000424.v7.p2)
- 666 GTEx (v7) eQTL summary statistics were downloaded from the GTEx Portal available at
- 667 <u>https://gtexportal.org/home/datasets</u>
- 668 Data from the TOPMed Women's Health Initiative is available from dbGaP (dbGaP Accession
- 669 phs001237)
- 670 UK Biobank (UKB) data was obtained under application number 24983 (PI: Dr. Manuel Rivas)
- 671 UKB Phase 1 GWAS summary statistics were downloaded from the Neale Lab server available at
- 672 <u>http://www.nealelab.is/uk-biobank</u>
- 673 Polygenic risk scores (PRS) for body mass index and type-2 diabetes were downloaded from the
- 674 Cardiovascular Disease Knowledge Portal available at http://kp4cd.org/dataset_downloads/mi
- 675 Gene annotation data was obtained from GENCODE (version 19) available at
- 676 https://www.gencodegenes.org/human/release_19.html
- 677 Allele frequency data was obtained from gnomAD (version r2.0.2) available at
- 678 <u>https://console.cloud.google.com/storage/browser/gnomad-public/release/2.0.2/</u>
- 679 hg19 coordinates were converted to hg38 using the chain file available at
- 680 <u>http://hgdownload.soe.ucsc.edu/goldenPath/hg19/liftOver/</u>
- 681 Custom scripts to conduct all analyses not performed using existing software can be found at
- 682 <u>https://github.com/csmail/outlier_prs</u>
- 683

684 Acknowledgements

685 CS is supported by NIH grant T32LM012409. NMF is supported by a National Science Foundation 686 Graduate Research Fellowship (grant number DGE 1656518) and a graduate fellowship from the Stanford 687 Center for Computational, Evolutionary and Human Genomics. MGD is supported by a National Science 688 Foundation Graduate Research Fellowship. MA is supported by the National Library of Medicine under 689 training grant T15LM007033. XL is supported by the National Natural Science Foundation of China (grant 690 number 31970554), National Key R&D Program of China (grant number 2019YFC1315804) and Shanghai 691 Municipal Science and Technology Major Project (grant number 2017SHZDZX01). MJG is supported by a 692 Stanford Graduate Fellowship. MAR is partially supported by Stanford University and a National Institute of 693 Health center for Multi- and Trans-ethnic Mapping of Mendelian and Complex Diseases grant (5U01 694 HG009080) and partially supported by the National Human Genome Research Institute (NHGRI) of the 695 National Institutes of Health (NIH) under award R01HG010140. SBM is supported by NIH grants 696 U01HG009431, R01HL142015, R01HG008150, R01AG066490 and U01HG009080. This research has 697 been conducted using the UK Biobank Resource under Application Number 24983, "Generating effective 698 therapeutic hypotheses from genomic and hospital linkage data" (http://www.ukbiobank.ac.uk/wp-699 content/uploads/2017/06/24983-Dr-Manuel-Rivas.pdf). Based on the information provided in Protocol 700 44532 the Stanford IRB has determined that the research does not involve human subjects as defined in

It is made available under a CC-BY-NC-ND 4.0 International license .

701 45 CFR 46.102(f) or 21 CFR 50.3(g). All participants of UK Biobank provided written informed consent. This 702 work in-part used supercomputing resources provided by the Stanford Genetics Bioinformatics Service 703 Center, supported by National Institutes of Health S10 Instrumentation Grant S10OD023452. The content 704 is solely the responsibility of the authors and does not necessarily represent the official views of the National 705 Institutes of Health. The WHI program is funded by the National Heart, Lung, and Blood Institute, National 706 Institutes of Health, U.S. Department of Health and Human Services through contracts 707 HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and 708 HHSN268201600004C. Molecular data for the Trans-Omics in Precision Medicine (TOPMed) program was 709 supported by the National Heart, Lung and Blood Institute (NHLBI). See the TOPMed Omics Support Table 710 below for study specific omics support information. Core support including centralized genomic read 711 mapping and genotype calling, along with variant guality metrics and filtering were provided by the TOPMed 712 Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Core support 713 including phenotype harmonization, data management, sample-identity QC, and general program 714 coordination were provided by the TOPMed Data Coordinating Center (R01HL-120393; U01HL-120393; 715 contract HHSN2682018000011). We gratefully acknowledge the studies and participants who provided 716 biological samples and data for TOPMed. This research is also supported by funding from the Department 717 of Veterans Affairs Office of Research and Development, Million Veteran Program (MVP) Grant I01-718 BX003340 and I01-BX003362. This publication does not represent the views of the Department of Veterans 719 Affairs or the United States Government. A list of MVP investigators can be found in supplementary 720 materials. The funders had no role in study design, data collection and analysis, decision to publish, or 721 preparation of the manuscript.

722

The authors would like to thank Jonathan Pritchard, Hakhamanesh Mostafavi, and members of the Pritchard Lab at Stanford University for helpful comments on this manuscript.

725

| TOPMed | TOPMed | Parent | TOPMed | Omics | Omics Support | Omics |
|-------------|---------|--------|--------|----------|-------------------|--------|
| Accession # | Project | Study | Phase | Center | | Туре |
| phs001237 | WHI | WHI | 2 | Broad | HHSN268201500014C | WGS |
| | | | | Genomics | | |
| phs001237 | WHI | WHI | 4 | Broad | HHSN268201600034I | RNASeq |
| | | | | Genomics | | |

726 TOPMed Omics Support Table

727

It is made available under a CC-BY-NC-ND 4.0 International license .

729 Author contributions

- 730 Conceptualization, C.S. and S.B.M.; Methodology, C.S. and S.B.M.; Software, C.S. and N.M.F.; Formal
- 731 Analysis, C.S., N.M.F., M.G.D., A.S.R., X.L., and M.J.G.; Investigation, C.S., N.M.F., M.G.D., A.S.R., and
- 732 S.B.M.; Data Curation, T.L.A., M.A., and M.A.R.; Resources, Q.H., J.H., T.L.A., C.J.O., Y.V.S., C.K., A.R.,
- and M.A.R.; Writing Original Draft, C.S. and S.B.M.; Writing Review & Editing, C.S., N.M.F., M.G.D.,
- A.S.R., M.A., Q.H., J.H., T.L.A., C.J.O., Y.V.S., M.A.R., C.K., A.R., and S.B.M.; Funding Acquisition, M.A.R.
- 735 and S.B.M.
- 736

737 Conflicts of interest

- 738 SBM is on SAB of Myome
- 739 SBM and CS report a patent application related to this work
- 740

It is made available under a CC-BY-NC-ND 4.0 International license .

741 References

- Khera, A. V. *et al.* Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood.
 Cell 177, 587–596.e9 (2019).
- Martin, A. R., Daly, M. J., Robinson, E. B., Hyman, S. E. & Neale, B. M. Predicting Polygenic Risk of Psychiatric Disorders. *Biol. Psychiatry* 86, 97–109 (2019).
- Filiott, J. *et al.* Predictive Accuracy of a Polygenic Risk Score–Enhanced Prediction Model vs a
 Clinical Risk Score for Coronary Artery Disease. *JAMA* 323, 636–645 (2020).
- Khera, A. V. *et al.* Genome-wide polygenic scores for common diseases identify individuals with risk
 equivalent to monogenic mutations. *Nat. Genet.* **50**, 1219–1224 (2018).
- 750 5. Zhang, Y. D. *et al.* Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. *Nat. Commun.* **11**, 3353 (2020).
- Aguilera, F. R.-M. *et al.* An integrated polygenic and clinical risk tool enhances coronary artery
 disease prediction. doi:10.1101/2020.06.01.20119297.
- 7. Yang, J. *et al.* Genetic variance estimation with imputed variants finds negligible missing heritability
 for human height and body mass index. *Nat. Genet.* 47, 1114–1120 (2015).
- 8. Mancuso, N. *et al.* The contribution of rare variation to prostate cancer heritability. *Nat. Genet.* 48, 30–35 (2016).
- Li, X. *et al.* The impact of rare variation on gene expression across tissues. *Nature* 550, 239–243 (2017).
- 760 10. Zhao, J. *et al.* A Burden of Rare Variants Associated with Extremes of Gene Expression in Human
 761 Peripheral Blood. *Am. J. Hum. Genet.* 98, 299–309 (2016).
- 11. Li, X. *et al.* Transcriptome sequencing of a large human family identifies the impact of rare noncoding
 variants. *Am. J. Hum. Genet.* **95**, 245–256 (2014).
- 12. Zeng, Y. et al. Aberrant gene expression in humans. PLoS Genet. 11, e1004942 (2015).
- Ferraro, N. M. *et al.* Diverse transcriptomic signatures across human tissues identify functional rare
 genetic variation. *bioRxiv* 786053 (2019) doi:10.1101/786053.
- 767 14. Bonder, M. J., Smail, C. *et al.*. Systematic assessment of regulatory effects of human disease
 768 variants in pluripotent cells. *bioRxiv* (2019).
- 769 15. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* 562, 203–209 (2018).
- Hurt, R. T., Kulisek, C., Buchanan, L. A. & McClave, S. A. The obesity epidemic: challenges, health
 initiatives, and implications for gastroenterologists. *Gastroenterol. Hepatol.* 6, 780 (2010).
- 17. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in 141,456
 humans. *Nature* 581, 434–443 (2020).
- 18. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting the
 deleteriousness of variants throughout the human genome. *Nucleic Acids Res.* 47, D886–D894
 (2019).
- Hernandez, R. D. *et al.* Ultrarare variants drive substantial cis heritability of human gene expression.
 Nature Genetics vol. 51 1349–1355 (2019).
- 20. Eyre-Walker, A. Genetic architecture of a complex trait and its implications for fitness and genomewide association studies. *Proceedings of the National Academy of Sciences* vol. 107 1752–1756
 (2010).
- Zeng, J. *et al.* Signatures of negative selection in the genetic architecture of human complex traits.
 Nat. Genet. 50, 746–753 (2018).
- 22. Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* 26, 841–842 (2010).
- 787 23. Pedersen, B. S., Layer, R. M. & Quinlan, A. R. Vcfanno: fast, flexible annotation of genetic variants.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 788 Genome Biol. **17**, 118 (2016).
- 789 24. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).
- 790 25. Churchhouse, C. Neale lab. <u>Details and considerations of the UK Biobank GWAS</u> (2017).
- 791 26. Stegle, O., Parts, L., Piipari, M., Winn, J. & Durbin, R. Using probabilistic estimation of expression
 792 residuals (PEER) to obtain increased power and interpretability of gene expression analyses. *Nat.*793 *Protoc.* 7, 500–507 (2012).
- Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage
 analyses. *Am. J. Hum. Genet.* 81, 559–575 (2007).
- Zhao, H. *et al.* CrossMap: a versatile tool for coordinate conversion between genome assemblies.
 Bioinformatics **30**, 1006–1007 (2014).
- Abraham, G., Qiu, Y. & Inouye, M. FlashPCA2: principal component analysis of Biobank-scale
 genotype datasets. *Bioinformatics* 33, 2776–2778 (2017).
- 800 30. Klarin, D. *et al.* Genetics of blood lipids among 300,000 multi-ethnic participants of the Million
 801 Veteran Program. *Nat. Genet.* **50**, 1514–1523 (2018).
- 802 31. Fang, H. *et al.* Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in Genome-wide
 803 Association Studies. *Am. J. Hum. Genet.* **105**, 763–772 (2019).
- 32. Wickham, H. ggplot2: Elegant Graphics for Data Analysis. (Springer, 2016).